PositoAI/ US/ Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

NasdaqGM: VERA · Healthcare

Positivity Index

#4,972 / 6,775

Global

#2,607 / 4,000

United States

Positivity Score

18,689

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Vera Therapeutics, Inc. — Overview & Financial Snapshot

Vera Therapeutics, Inc. (NasdaqGM: VERA) is a Healthcare company, ranked #4,972 of 6,775 companies globally and #2,607 of 4,000 in United States on PositoAI, with a Positivity Score of 18,689. Its market capitalisation is ₹19,760.15 Cr ($2.09B), P/E ratio is -4.9 and P/B ratio is 5.13. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

P/B Ratio 5.13

P/E Ratio -4.9

D/E Ratio 0.19

ROE -91.75%

Owes vs Owns ? 0.23× Low $0.23 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-554.07$-5.87

Forward EPS ₹-401.27$-4.25

Beta 1.05

Market Cap ₹19,760.15 Cr$2.09B

What these numbers mean →

What does Vera Therapeutics, Inc. do?

What is Vera Therapeutics, Inc.'s P/E and P/B ratio?

Vera Therapeutics, Inc. has a P/E ratio of -4.9 and a P/B ratio of 5.13.

What is Vera Therapeutics, Inc.'s debt-to-equity ratio?

Vera Therapeutics, Inc. has a debt-to-equity ratio of 0.19.

How much does Vera Therapeutics, Inc. owe compared with what it owns?

Vera Therapeutics, Inc. owes $0.23 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Vera Therapeutics, Inc.'s Positivity rank?

Vera Therapeutics, Inc. is ranked #4,972 of 6,775 companies globally and #2,607 of 4,000 in United States on PositoAI, with a Positivity Score of 18,689.

Does Vera Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Vera Therapeutics, Inc..

Where can I read the latest news about Vera Therapeutics, Inc.?

Recent headlines about Vera Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Vera Therapeutics, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Vera Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.